Third, while cetuximab resistance mechanisms limit the effectiveness of anti-EGFR treatments and promote tumor cell survival, they are unable to prevent granzyme B (GZMB)-induced apoptosis by healthy NK cells following cetuximab treatment (82–85). This evidence concerns the gene GZMB and neoplasm.